The prevalence of T2DM continues to increase worldwide. One of every 10 Americans has T2DM, the main cause of CKD and end-stage kidney disease. Approximately 36% of those with T2DM have CKD.[@bib1], [@bib2] Other risk factors for CKD, including hypertension, obesity, and hyperuricemia, are common in patients with T2DM. Hispanic individuals, the largest ethnic minority in the United States, are at increased risk for both T2DM and CKD.[@bib3], [@bib4] The prevalence of T2DM in Hispanic individuals is approximately 12.1% compared with 7.4% in non-Hispanic white individuals.[@bib1], [@bib5] CKD progresses faster in Hispanic individuals compared with non-Hispanic white individuals.[@bib6] Since 2002, the Latino Diabetes Initiative, a culturally appropriate program intended at improving T2DM outcomes in Hispanic individuals at the Joslin Diabetes Center, aims to decrease diabetes complication rates and promote diabetes prevention for future generations. Here we report the kidney outcomes of patients followed for 13 years by the Latino Diabetes Initiative.

Methods {#sec1}
=======

Population Selection {#sec1.1}
--------------------

In this retrospective cohort study, the population consisted of patients with T2DM and Hispanic background seen at the Joslin Diabetes Center in Boston, MA, between July 2002 and July 2015. A total of 920 patients met the inclusion criteria. Subjects were excluded if they had only 1 medical visit (*n* = 171), a single creatinine measure (*n* = 127), or if they had end-stage kidney disease (dialysis or transplant) at baseline (*n* = 4). The final cohort included 594 participants. The study was approved by the Institutional Review Board at the Joslin Diabetes Center.

Clinical Variables {#sec1.2}
------------------

Demographic, clinical, and biochemical variables were assessed. Glycated hemoglobin (HbA1c), lipid panel (total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol), blood pressure (BP), and kidney function tests (estimated glomerular filtration rate by CKD-Epidemiology Collaboration \[eGFR\] and urine albumin-creatinine ratio \[ACR\]) were obtained from clinical. The number of medical appointments with endocrinology and nephrology providers was determined. CKD was defined by either decreased eGFR (\<60 ml/min per 1.73 m^2^) and/or the presence of albuminuria based on spot urine samples using sex-specific cutoffs (urine ACR \>17 mg/g in men and \>25 mg/g in women). Severe albuminuria was defined as ACR \>300 mg/g. The population was stratified according to the rate of glomerular filtration rate loss per year. Annualized based of loss of glomerular filtration rate was defined as the difference between first and last glomerular filtration rate over time (years). Rapid progression was defined as loss of \>3 ml/min per year in eGFR. Adequate control was defined as the following: BP when both systolic BP (SBP) \<130 mm Hg and diastolic BP \<80 mm Hg; whereas diabetes control was defined as HbA1c \<7%, lipid control was defined as low-density lipoprotein cholesterol \<100 mg/dl, and weight was defined as body mass index between 20 and 25 kg/m^2^.

Statistical Analysis {#sec1.3}
--------------------

To assess differences between groups we performed *t*-test and χ^2^ test as appropriate. Pearson correlation was used to evaluate the relationship between clinical parameters to determine variables to be included in the multivariable models. A mixed linear model was used to assess if eGFR was associated with a number of clinical and anthropometric variables. Cox regressions were used to evaluate risk of developing CKD based on baseline characteristics. This technique also was used to evaluate risk using longitudinal data. In addition, Kaplan-Meier survival analysis was used to depict incident CKD in the population. Analysis was performed using SAS 9.4 (SAS Institute, Inc., Cary, NC).

Results {#sec2}
=======

[Table 1](#tbl1){ref-type="table"} summarizes the demographic and clinical parameters stratified by progression status. More than half of the cohort was female (57.4%). The mean and SD for the following variables at baseline were age 56.6 ± 12.2 years, HbA1c 8.87% ± 2.08%, low-density lipoprotein cholesterol 105.74 ± 37.85 mg/dl, eGFR 86.51 ± 23.44 mL/min per 1.73 m^2^, urine ACR 160.08 ± 655.68 mg/g, SBP 128.54 ± 17.84 mm Hg, diastolic BP 75.26 ± 9.6 mm Hg, and body mass index 32.02 ± 6.46 kg/m^2^. The mean duration of T2DM was 18 ± 9.5 years.Table 1Baseline demographic and clinical characteristics stratified by glomerular filtration rate lossVariableAll subjects, mean ± SD,\
*n* = 594Slow progressors, mean ± SD, *n* = 448Rapid progressors, mean ± SD, *n* = 146*P*Female gender (%)57.456.360.70.35Marital status (%)0.75 Single35.734.335.7 Married49.150.949.1 Divorced7.46.87.4 Widowed3.83.683.8 Separated4.04.34.0Education (%)0.86 Less than high school54.754.555.3 High school45.345.544.7 Smoker (%)39.738.443.60.26 Age (yr)56.6 ± 12.256.4 ± 12.257.2 ± 12.10.47 T2DM duration (yr)18.4 ± 9.518.1 ± 9.619.4 ± 9.20.15 BMI (kg/m^2^)32.0 ± 6.532.3 ± 6.631.8 ± 6.20.72 HbA1c (%)8.9 ± 2.18.76 ± 2.09.2 ± 2.30.04 Cr (md/dl)0.9 ± 0.40.91 ± 0.40.8 ± 0.40.11 eGFR (ml/min per 1.73 m^2^)86.5 ± 23.485.8 ± 23.788.8 ± 22.80.24 Urine ACR (mg/gr) (median, range)15.1, 7983.1913.4, 5639.120.9, 7982.10.02 Blood pressure (mm Hg) SBP128.5 ± 17.8127.6 ± 17.7131.2 ± 17.90.04 DBP75.3 ± 9.674.9 ± 9.676.2 ± 9.70.22 Lipid profile (mg/dl) Cholesterol185.6 ± 45.2186.1 ± 44.3183.9 ± 47.90.66 LDL105.7 ± 37.9107.3 ± 36.7101.1 ± 40.90.15 TGL214.8 ± 215.1205.8 ± 138.0242.4 ± 359.70.13 HDL45.8 ± 13.145.5 ± 13.346.6 ± 12.50.47[^1][^2]

More than a third (35.8%) of participants had eGFR \<60 ml/min per 1.73 m^2^ and 28.48% had albuminuria at baseline. Both albuminuria and eGFR \<60 ml/min per 1.73 m^2^ were found in 5.28% of our cohort. In patients \<50 years old, 26.67% had eGFR \<60 ml/min per 1.73 m^2^ and 27.88% had albuminuria. In patients \>65 years old, 51.94% had eGFR \<60 ml/min per 1.73 m^2^ and 29.46% had albuminuria. In women, 34.9% had eGFR \<60 ml/min per 1.73 m^2^ and 24.93% had albuminuria. Moderate and severe albuminuria were found in 39.1% and 8.6%, respectively. Participants with albuminuria at baseline had on average 2.53 ± 1.56 endocrine appointments and 0.52 ± 1.35 nephrology appointments per year. Participants with eGFR\<60 ml/min per 1.73 m^2^ had on average 2.58 ± 1.61 endocrine appointments and 0.33 ± 1.04 nephrology appointments per year.

Twenty-five percent of participants had rapid kidney function decline. Participants with rapid CKD progression were more likely to have higher HbA1c, urine ACR, and SBP at baseline. Lipid profiles, smoking history, and eGFR at baseline was not different between rapid and slow progressors.

The mean annual rate of renal function decline in our cohort was −1.39 ml/min ± 14.62. In participants with eGFR\<60 ml/min per 1.73 m^2^ or albuminuria at baseline, the decline was −1.26 ± 16.63 ml/min and −0.67 ± 12.83 ml/min, respectively. Participants with severe albuminuria had an annual decline in renal function of −4.95 ± 10.15 ml/min.

Using a mixed linear model, an inverse association was seen between eGFR and age (*P* \< 0.01). Higher SBP and diastolic BP values were associated with higher eGFR at baseline (*P* \< 0.05). Variations in ACR and HbA1c did not affect eGFR throughout the follow-up (*P* = 0.16 and *P* = 0.41, respectively).

In a multivariable model, having uncontrolled BP (HR: 1.72; 95% CI: 1.18--2.51; *P* = 0.005) and being overweight (HR: 2.68; 95% CI: 1.13--6.38; *P* = 0.026), but not having uncontrolled T2DM (HR: 0.92; 95% CI: 0.55--1.55; *P* = 0.75) at baseline was associated with increased risk of incident CKD. Participants with T2DM duration of more than 18 years at baseline (mean diabetes duration) had significantly increased risk of developing CKD (HR: 1.11; 95% CI: 1.08--1.14; *P* \< 0.0001) during follow-up. Female gender and age older than 65 years at baseline increased the risk as well (HR: 1.64; 95% CI: 1.14--2.35; *P* = 0.008 and HR: 1.03; 95% CI: 1.02--1.05; *P* \< 0.0001, respectively). Interestingly, absence of smoking history increased the risk of developing CKD (HR: 1.54; 95% CI: 1.04--2.28; *P* = 0.031) ([Table 2](#tbl2){ref-type="table"}).Table 2Risk of developing chronic kidney disease during follow-up based on baseline characteristicsBaseline characteristicsPercentage of total populationUnadjustedMultivariable model[a](#tbl2fna){ref-type="table-fn"}HR (95% CI)*P* valueHR (95% CI)*P* valueUncontrolled T2DM78.52.02 (1.66--2.46)\<0.00010.92 (0.55--1.55)0.753Uncontrolled BP27.91.82 (1.51--2.19)\<0.00011.72 (1.18--2.5)0.005High LDL51.50.81 (0.69--0.95)0.0120.87 (0.62--1.21)0.395Overweight91.81.64 (1.61--2.31)0.0052.68 (1.13--6.38)0.026No smoking history60.31.26 (1.11--1.43)0.00041.54 (1.04--2.28)0.031Age at first visit (\>65 yr)21.71.03 (1.03--1.04)\<0.00011.03 (1.02--1.05)\<0.0001Gender (female)57.40.67 (0.59--0.77)\<0.00011.64 (1.14--2.35)0.008T2DM duration (\>18 yr)46.31.02 (1.01--1.02)\<0.00011.11 (1.08--1.14)\<0.0001[^3][^4]

During follow-up, an increased risk of developing CKD was found with higher SBP (HR: 1.01; 95% CI: 1.006--1.02; *P* = 0.0002), HbA1c (HR: 1.18; 95% CI: 1.099--1.258; *P* \< 0.0001), or older age (HR: 1.03; 95% CI: 1.015--1.037; *P* \< 0.0001). Statin use was associated with reduced risk of developing CKD (HR: 0.52; 95% CI: 0.42--0.65; *P* \< 0.0001), whereas use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was associated with increased incidence of CKD ([Table 3](#tbl3){ref-type="table"}).Table 3Chronic kidney disease development risk and clinical characteristics during the follow-upVariables during follow-upUnadjustedMultivariable model[a](#tbl3fna){ref-type="table-fn"}HR (95% CI)*P* valueHR (95% CI)*P* valueHbA1c (per %)1.11 (1.05--1.18)0.00041.17 (1.01--1.26)\<0.0001BP (per mm Hg) SBP1.01 (1.01--1.02)\<0.00011.01 (1.01--1.02)0.0002 DBP1.00 (0.99--1.01)0.8810.99 (0.97--1.00)0.053Age at first visit (per yr)1.03 (1.03--1.04)\<0.00011.03 (1.02--1.04)\<0.0001ACEI or ARB use1.77 (1.4--2.24)\<0.00011.53 (1.03--2.29)0.0379Statin use0.66 (0.56--0.78)\<0.00010.52 (0.42--0.65)\<0.0001[^5][^6]

In patients who did not have CKD at baseline and developed CKD during follow-up, the mean time to development of CKD was 7.8 years (SD 0.12).

[Figure 1](#fig1){ref-type="fig"} shows the predicted eGFR at 25 years of follow-up for different populations (including our cohort) using previously reported annual rates. There is clear evidence of worse renal outcomes for the Hispanic population compared with the general US population, as well as with those with T2DM.Figure 1Predicted estimated glomerular filtration rate (eGFR) at 25 years of follow-up. Initial eGFR was defined as 90 ml/min per 1.73 m^2^ for all groups. The estimated annual rates of renal function decline previously described were as follows: non--type 2 diabetes mellitus (T2DM) US population (red), --0.3 ml/min; US + T2DM population (green), --0.71 ml/min; non-T2DM Hispanic/Latino population (blue), --1.25 ml/min; estimated annual rate of renal function decline in our cohort at Joslin Diabetes Center's Latino Diabetes Initiative (LDI; yellow), --1.39 ml/min.

Discussion {#sec3}
==========

We report that Hispanic patients with T2DM have a high prevalence for eGFR \<60 ml/min per 1.73 m^2^ and albuminuria. A quarter of participants had rapid kidney function decline. Our study provides support that glucose control and BP control are essential to slow progression of diabetes. We did not find an association among smoking history, lipid profile, and CKD progression, perhaps influenced by survival bias.

T2DM prevalence has been estimated as 9.4% in the United States and it is expected to continue increasing over time.[@bib1] CKD is a common microvascular complication in patients with T2DM, increasing morbidity and mortality as well as costs for health systems worldwide.[@bib2] Hispanic populations are among those with the highest prevalence of T2DM and CKD worldwide. Moreover, prognosis and outcomes tend to be worse in this ethnic group. Prevalence of impaired eGFR and albuminuria in the Hispanic population without T2DM in the United States were estimated as 2.75% and 13.54%, respectively[@bib6]; compared with 35.5% and 28.8%, respectively, in our cohort. Previous reports have shown that Hispanic individuals with T2DM have lower prevalence of albuminuria (structural damage), yet higher prevalence of impaired eGFR (functional damage) compared with non-Hispanic white individuals, leading to higher end-stage kidney disease prevalence.[@bib7]

The mean annual rate of kidney function decline in our Hispanic population with T2DM was −1.39 ml/min per 1.73 m^2^. A mean annual decline in renal function for the US population without T2DM or CKD was estimated to be −0.3 ml/min; for the Hispanic population without T2DM it was found to be considerably higher (−1.25 ml/min).[@bib8], [@bib9] Patients with T2DM in the United States, had a mean reported annual decline of −0.71 ml/min.[@bib8] Of note, higher annual decline of kidney function was expected in our population. Our findings might suggest a benefit from a cultural-approach intervention provided at Joslin with frequent follow-up; however, because no control group was included in our study, this assumption cannot be proven with our findings.

Even though recent studies have described lower cardiovascular events and overall mortality in Hispanic patients with T2DM,[@bib10], [@bib11] our findings support the susceptibility of the Hispanic population to worse kidney outcomes. Culturally appropriate treatment programs tailored to the Hispanic community are needed to decrease the kidney disease burden.

Conclusion {#sec4}
==========

Hispanic individuals with diabetes are at increased risk of developing rapidly progressing CKD. Several modifiable risk factors are associated with rapid CKD progression. Public health measures to improve BP control and obesity, appropriately targeted to this high-risk population, are needed.

Limitations {#sec4.1}
-----------

Although our study includes several strengths, including the extensive follow-up, we must acknowledge several limitations. Our analyses were limited to data collected for clinical purposes. In addition, our center is a multispecialty referral center for diabetes care, which may not be representative of Hispanic individuals in every community. Last, the Hispanic community in Boston is composed of individuals mostly of Puerto Rican and/or Dominican origin (95% among Hispanic population).[@bib12] Therefore, it may not be representative of all Hispanic individuals in the United States where two-thirds are of Mexican descent.
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**STROBE Statement**.

[^1]: ACR, albumin-creatinine ratio; BMI, body mass index; Cr, creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; TGL, triglycerides; T2DM, type 2 diabetes mellitus.

[^2]: Data are mean ± SD unless otherwise indicated.

[^3]: BP, blood pressure; CI, confidence interval; HR, hazard ratio; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.

[^4]: Adjusted for all variables included in the table and statin therapy use.

[^5]: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BP, blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HR, hazard ratio; SBP, systolic blood pressure.

[^6]: Adjusted for gender in addition to all variables included in the table.
